S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Vertex Pharmaceuticals Inc

VRTX XNAS
$435.17 +5.35 (+1.24%) ▲ 15-min delayed
Open
$429.50
High
$442.15
Low
$428.50
Volume
1.26M
Market Cap
$109.09B

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 6.4K Website →

Key Financials

Period Revenue Net Income EPS
Q1 2026 $2.99B $1.03B $4.06
FY 2025 $12.00B $3.95B $15.46
Q3 2025 $3.08B $1.08B $4.24
Q2 2025 $2.96B $1.03B $4.02

Get VRTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Vertex Pharmaceuticals Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.